The latest market report published by Credence Research, Inc. “Global Listeria monocytogenes Infections Treatment Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2022,” the Listeria monocytogenes infections treatment market was valued at USD 3,624.9 Mn in 2015, and is expected to reach USD 5,056.3 Mn by 2022, expanding at a CAGR of 4.74% from 2016 to 2022.
Browse the full report Listeria monocytogenes Infections Treatment Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at http://www.credenceresearch.com/report/listeria-monocytogenes-infections-treatment-market
Listeria monocytogenes, is an important pathogen in pregnant patients, neonates, elderly individuals, and immunocompromised individuals, although an uncommon cause of illness in the general population. Listeria monocytogenes is a bacterial pathogen capable of causing severe infections in humans, often with fatal outcomes. According to USFDA, published studies suggest that 1- 8% of humans may be intestinal carriers of Listeria. According to Unites States Department of Agriculture (USDA), Listeria causes about 280 cases of illness in newborns in a typical year, resulting in 60 deaths and stillbirths. Infants can be infected before birth, and this infection can cause serious disability in newborns. About 35 infants are disabled as a result of infection from Listeria each year. The key factors assisting the growth of Listeria monocytogenes infections treatment market are rise in prevalence of foodborne diseases, stringent laws and policies issued by FDA, rising demand for healthy and microbial-free food, and high public awareness related to foodborne diseases in developed countries.
The phase III drugs included in the pipeline analysis are Carbavance (The Medicines Company), Telavancin (Theravance Biopharma Antibiotics, Inc.), Daptomycin (Merck & Co.), Prulifloxacin (Merck & Co.), and DTaP-IPV/Hib combined vaccine (Sanofi S.A.). According to market experts, the diversity of the several molecule types in the biologic group shows a certain level of innovation, with newer avenues being explored in accounts of recent failures. Overall, late stage clinical trials have highlighted very few molecules that could potentially replace current treatments during the forecast period.
Request Free Sample : http://www.credenceresearch.com/sample-request/57831
Key Market Movements
Credence Research is a worldwide industry research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE,
CA 95103, United States